NOWDiagnostics First To Know® Syphilis Test Receives FDA De Novo Marketing Authorization for Over-the-Counter Use

Written by Todd Simpson

In The News

NOWDx Submits De Novo Classification Request to the FDA for Its First to Know™ Over-the-Counter Syphilis Test
NOWDiagnostics First To Know® Syphilis Test Receives FDA De Novo Marketing Authorization for Over-the-Counter Use
NOWDiagnostics Secures $22.5 Million in Series B Funding

Past Stories

NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board
Dr. Jody Douglas Berry Joins NOWDx as Chief Scientific Officer
NOWDx Submits De Novo Classification Request to the FDA for Its First to Know™ Over-the-Counter Syphilis Test
NOWDiagnostics Hires Todd Grice as VP of Sales
NOWDx and AeenaDx Announce Merger
NOWDiagnostics Introduces the Direct Collect
NOWDiagnostics Completes Syphilis Test Matrix Comparison Study
NOWDiagnostics granted CE Mark for Rapid Syphilis Test
NEW Automation Capacity Yields 2M Tests/Month
NOWDiagnostics Announces Jim Haworth as Executive Chairman of the Board of Directors
ADEXUSDx® COVID-19 Antibody Test Receives FDA Emergency Use Authorization
University of Milan Study Finds Self-Contained, Rapid ADEXUSDx® COVID-19 Antibody Test has 100% Specificity
NWA's NOWDiagnostics Chosen as Endeavor Entrepreneur at 7th Virtual International Selection Panel
BARDA and NOWDiagnostics Partner to Develop Rapid COVID-19 Antibody Test for Use Point-of-Care and At-Home
ADEXUSDx® COVID-19 Test Receives Conformité Européene (CE) Mark Approval
It’s Official! NOWDx Acquires CELLMIC Reader Technology
Now Diagnostics’ Rapid Blood Pregnancy Test Receives Approval in Europe for Over-The-Counter Sales
NOWDiagnostics Inc. Acquires Canada’s ZBx Corporation
FDA Clears NOWDiagnostics’ ADEXUSDx® hCG Test for Professional Use